OncoMatch/Clinical Trials/NCT05564377

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Is NCT05564377 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for advanced malignant solid neoplasm.

Treatment: Alpelisib · Binimetinib · Fluorouracil · Fulvestrant · Ipatasertib · Leucovorin · Neratinib Maleate · Nilotinib Hydrochloride Monohydrate · Olaparib · Oxaliplatin · Paclitaxel · Palbociclib · Panitumumab · Selumetinib Sulfate · Sotorasib — This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.